The characteristics and outcomes of patients with multiple myeloma dual refractory or intolerant to bortezomib and lenalidomide in the era of carfilzomib and pomalidomide
Tzu Fei Wang, Rohan Ahluwalia, Mark A. Fiala, Kathryn M. Trinkaus, Doug P. Cox, Matthew Jaenicke, Caitlin C. Moliske, Kenneth R. Carson, Tanya M. Wildes, Michael H. Tomasson, Keith E. Stockerl-Goldstein, Ravi Vlj*
Dive into the research topics of 'The characteristics and outcomes of patients with multiple myeloma dual refractory or intolerant to bortezomib and lenalidomide in the era of carfilzomib and pomalidomide'. Together they form a unique fingerprint.